1. Reconciled Gastroenterology, Hepatology, and Renal Execution & Stop-Cause Profile
| Clinical Trial Metric | Verified Value | Operational Context |
|---|---|---|
| Total Phase II & III Protocols (2018 to 2026) | 1,088 | Deterministic primary MeSH and condition-keyword assignment |
| Active Concurrent Pipeline | 422 | Recruiting, enrolling by invitation, and active follow-up protocols |
| Completed vs Prematurely Stopped | 396 / 140 | 26.12% closed-trial attrition ratio across 536 closed protocols |
| Slow Accrual vs Safety & Futility Stops | 33 / 15 / 13 | Slow accrual (WS1) vs clinical safety (WS4) vs interim futility (WS5) |
| Physical Hospital Site Disclosure Rate | 71.5% | Named hospital campus participations vs anonymized CRO site slots |
2. Leading Consolidated Trial Sponsors Focused on Gastroenterology, Hepatology, and Renal
| Sponsor Hub | Sector | Protocols | Active | Completed | FDA NDA/BLA |
|---|---|---|---|---|---|
| Mirum Pharmaceuticals | Biopharma Industry | 16 | 8 | 6 | 0 |
| Zealand Pharma | Biopharma Industry | 16 | 2 | 13 | 1 |
3. Representative Multi-Center Phase II & III Gastroenterology, Hepatology, and Renal Studies
| NCT Study | Protocol Brief Title | Sponsor | Phase | Status |
|---|---|---|---|---|
| NCT07282353 | A Study of CS0159 in Patients With PBC With Inadequate Response or Intolerance to UDCA | Cascade Pharmaceuticals | Phase III | RECRUITING |
| NCT05931276 | CSP #2026 - Beta Blocker Dialyzability on Cardiovascular Outcomes | VA Office of Research and Development | Phase III | RECRUITING |
| NCT06470191 | A Clinical Study of B007 in the Treatment of Primary Membranous Nephropathy. | Shanghai Jiaolian Drug Research and Development Co | Phase II/III | RECRUITING |
| NCT07803965 | Study of SGC001 Injection for Predicted Severe Acute Pancreatitis to Assess Safety, Tolerability and Preliminary Efficacy | Beijing Sungen Biomedical Technology Co | Phase II | RECRUITING |
| NCT06962800 | A Study to Learn More About the Effects and Safety of Felzartamab Infusions in Adults With Primary Membranous Nephropathy (PMN) | Biogen | Phase III | RECRUITING |
| NCT06593392 | Safety and Tolerability of Difelikefalin in Adolescents on Haemodialysis With Moderate-to-Severe Pruritus | Vifor Fresenius Medical Care Renal Pharma | Phase II | RECRUITING |
| NCT05457283 | A Study to Learn More About How Safe the Study Treatment Finerenone is in Long-term Use When Taken With an ACE Inhibitor or Angiotensin Receptor Blocker Over 18 Months of Use in Children and Young Adults From 1 to 18 Yea | Bayer | Phase III | RECRUITING |
| NCT06933472 | A Study of a Novel Iron-based Phosphate Binder AP301 in Patients With Hyperphosphatemia in the U.S. and China | Alebund Pharmaceuticals | Phase III | RECRUITING |
| NCT07159841 | A Study in Pediatric Participants With Congenital Adrenal Hyperplasia (Balance-CAH) | Crinetics Pharmaceuticals | Phase II/III | RECRUITING |
| NCT04924868 | Ursodeoxycolic Acid for the Prevention of Relapsing Complications After Gallstone Acute Pancreatitis | Hospital General Universitario de Alicante | Phase III | RECRUITING |
| NCT03949855 | Belimumab With Rituximab for Primary Membranous Nephropathy | National Institute of Allergy and Infectious Diseases (NIAID) | Phase II | RECRUITING |
| NCT06080789 | A Study to Evaluate the Safety and Efficacy of a Single Dose of RABI-767 in Participants With Acute Pancreatitis | Panafina | Phase II | RECRUITING |
| NCT06466785 | A Phase 3 Study of Efepoetin Alfa for Treatment of Anemia in Patients With Chronic Kidney Disease on Dialysis | Genexine | Phase III | RECRUITING |
| NCT03684278 | Randomised Treatment of Acute Pancreatitis With Infliximab: Double-blind, Placebo-controlled, Multi-centre Trial (RAPID-I) | University of Liverpool | Phase II | RECRUITING |
| NCT06963827 | A Study of Mezagitamab in Adults With Kidney Condition Called IgA Nephropathy | Takeda | Phase III | RECRUITING |
| NCT07387549 | A Study to Assess How Well and Safely Elafibranor Works in Adult Participants With Primary Sclerosing Cholangitis | Ipsen | Phase III | RECRUITING |
Related Therapeutic Condition Hubs & Crosswalks
Compare adjacent clinical cohorts: Oncology and Hematology · Rare Genetic, Women's Health, and Other · Infectious Disease and Vaccines · Neurology, Psychiatry, and Pain, browse the interactive Hospital & Sponsor Directory, or read the Healthcare Price & Patent Cliff Crosswalk.